Welcome to our dedicated page for CERO THERAPEUTICS HOLDINGS SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERO THERAPEUTICS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERO THERAPEUTICS HOLDINGS's regulatory disclosures and financial reporting.
CERo Therapeutics Holdings, Inc. files its annual report describing progress on CER-1236, an autologous engineered T cell therapy targeting TIM-4 ligand for cancer. The company is running a first-in-human Phase 1/1b trial in acute myeloid leukemia, with five patients treated as of March 2026 and no dose-limiting toxicities reported to date.
CER-1236 has received FDA Orphan Drug Designation and Fast Track Designation for AML, and the trial has been expanded to include myelodysplastic syndrome and myelofibrosis. A separate Phase 1 study in non-small cell lung cancer and ovarian cancer is anticipated to begin in 2026. As of April 14, 2026, 36,786,686 shares of common stock were outstanding.
Cero Therapeutics Holdings, Inc. files Prospectus Supplement No. 7 to its Form S-1 registering 729,596,950 shares of common stock.
The supplement attaches a Form 8-K that discloses a convertible promissory note: a $350,000 purchase (principal face value $437,500) under a facility allowing borrowings up to $1,000,000, bearing interest at 10%, maturing April 9, 2027, and convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the prior 20 days, subject to a 4.99% beneficial ownership cap. The note requires registration of conversion shares on Form S-1 or S-3.
CERO Therapeutics Holdings, Inc. entered into a financing deal by issuing a convertible promissory note to Keystone Capital Partners for a purchase price of $350,000, with a principal face value of $437,500. Under this Note, the company may borrow up to an aggregate $1,000,000.
The Note bears 10% annual interest, matures on April 9, 2027, and can be converted into common stock at the lender’s option at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership cap.
The transaction was conducted as a private placement to an accredited investor under Section 4(a)(2) and Rule 506(b) of the Securities Act, and the company agreed to file a registration statement on Form S-1 or S-3 to cover resale of the conversion shares.
CERo Therapeutics Holdings, Inc. notified the SEC on Form 12b-25 that it could not timely file its Annual Report on Form 10-K for the year ended December 31, 2025 and expects to file within the fifteen calendar days allowed under Rule 12b-25. The company says it engaged a new independent auditor in February 2026, and the new auditor requires additional time to complete its review.
The filing discloses preliminary results as of March 31, 2026: an estimated net loss of $19.9 million for the year ended December 31, 2025 versus $8.3 million in the prior year, and $16.2 million of cash used in operating activities in 2025 versus $12.9 million in 2024. These figures are preliminary and subject to change in the completed Form 10-K.
CERO THERAPEUTICS HOLDINGS, INC. reports that Isaiah Tibbs beneficially owns 1,830,007 shares of Common Stock, representing 8.67% of the class. The filing states Tibbs has sole power to vote and sole dispositive power over all 1,830,007 shares.
CERO Therapeutics Holdings, Inc. registered 729,596,950 shares of Common Stock via a Prospectus Supplement. The supplement attaches a Form 8-K that discloses the issuance of a convertible promissory note with a purchase price of $750,000 (principal face value $937,500) and an available facility up to $1,000,000.
The Note bears interest at 10% per annum, matures on August 6, 2027, and is convertible at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the 20 trading days before a conversion request, subject to a 4.99% beneficial ownership limit. The Prospectus Supplement states a registration statement will cover resale of shares issuable upon conversion.
CERo Therapeutics Holdings, Inc. entered into a material definitive financing agreement by issuing and selling a convertible promissory note to Keystone Capital Partners, LLC for a purchase price of $750,000, with a principal face value of $937,500 and total borrowing capacity up to $1,000,000.
The note bears 10% annual interest, matures on August 6, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior twenty days, subject to a 4.99% beneficial ownership limit. The company must file a registration statement on Form S-1 or S-3 to cover resale of conversion shares, and the issuance relied on private offering exemptions under Sections 4(a)(2) and 3(a)(9) and Rule 506(b) of the Securities Act.
CERO Therapeutics is supplementing its Form S-1 to register 729,596,950 shares of Common Stock via Prospectus Supplement No. 5.
The supplement attaches a Form 8-K disclosing a $750,000 convertible note (principal face value $937,500) that permits up to $1,000,000 of borrowings, bears 10% interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the preceding 20 days, subject to a 4.99% beneficial ownership limit. The Note requires the company to file a registration statement covering resale of conversion shares.
The Form 8-K also reports dismissal of auditor Wolf & Company, P.C. and appointment of Salberg & Company, P.A. effective February 13, 2026, with Wolf’s prior audit reports including an explanatory paragraph about substantial doubt as to going concern. The Board increased from six to seven members and appointed Eric Francois as a director, effective February 13, 2026.
CERO Therapeutics Holdings, Inc. entered into a financing agreement by issuing a convertible promissory note to Keystone Capital Partners for a $750,000 purchase price with a principal face value of $937,500, allowing total borrowings up to $1,000,000. The note bears 10% annual interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership limit. The company plans to file a registration statement covering resale of conversion shares. CERO’s audit committee dismissed Wolf & Company, P.C. as independent auditor and appointed Salberg & Company, P.A., following prior audit reports that included a going concern explanatory paragraph and a material weakness in internal controls. The board also expanded from six to seven members and appointed Eric Francois as a new director, with an expectation he will stand for election at the 2026 annual meeting.
Cero Therapeutics Holdings, Inc. has registered 729,596,950 shares of common stock under a Form S-1, and this Prospectus Supplement No. 4 updates that registration by incorporating information from a newly filed Current Report on Form 8-K.
The 8-K adds a poster presentation that the company prepared for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026, filed as Exhibit 99.1. Cero’s common stock trades on OTCQB under “CERO” and its public warrants trade on OTCID under “CEROW.” On February 3, 2026, the last quoted bid prices were $0.05 per share of common stock and $0.0068 per warrant.
The company is classified as an emerging growth company and highlights that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the base prospectus. The poster is described as summary information and is intended to be read together with the company’s other SEC filings and public announcements.